BOT Stock Overview
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Botanix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.32 |
| 52 Week High | AU$0.45 |
| 52 Week Low | AU$0.14 |
| Beta | 1.87 |
| 11 Month Change | -0.78% |
| 3 Month Change | -10.56% |
| 1 Year Change | 104.84% |
| 33 Year Change | 466.96% |
| 5 Year Change | 188.64% |
| Change since IPO | 958.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0.8% | -16.4% | 0.9% |
| 1Y | 104.8% | 32.2% | 18.4% |
Return vs Industry: BOT exceeded the Australian Pharmaceuticals industry which returned 35% over the past year.
Return vs Market: BOT exceeded the Australian Market which returned 17.7% over the past year.
Price Volatility
| BOT volatility | |
|---|---|
| BOT Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 11.8% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: BOT has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: BOT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Howie McKibbon | www.botanixpharma.com |
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
Botanix Pharmaceuticals Limited Fundamentals Summary
| BOT fundamental statistics | |
|---|---|
| Market cap | AU$581.59m |
| Earnings (TTM) | -AU$13.87m |
| Revenue (TTM) | AU$2.07m |
281.0x
P/S Ratio-41.9x
P/E RatioIs BOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOT income statement (TTM) | |
|---|---|
| Revenue | AU$2.07m |
| Cost of Revenue | AU$3.65m |
| Gross Profit | -AU$1.58m |
| Other Expenses | AU$12.29m |
| Earnings | -AU$13.87m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0076 |
| Gross Margin | -76.48% |
| Net Profit Margin | -670.20% |
| Debt/Equity Ratio | 0% |
How did BOT perform over the long term?
See historical performance and comparison